Lesser-Known Lobular Breast Cancer on the RiseLesser-Known Lobular Breast Cancer on the Rise
Invasive lobular carcinoma is now increasing faster than other types of breast cancers among US women. A recent study published in Cancer found that new cases of lobular breast cancer, which originates in the milk-producing glands, are climbing at a rate of nearly 3% per year, compared with less than 1% for all other breast cancers combined. As of 2021, 14 cases per 100 000 women with invasive lobular carcinoma have been reported, which accounted for 10% of breast cancer cases.
Ozempic Drug Fails to Quell Alzheimer’s in Novo Nordisk TrialsOzempic Drug Fails to Quell Alzheimer’s in Novo Nordisk Trials
The studies were a significant setback for the optimistic view that semaglutide and other GLP-1 drugs could help prevent a number of brain diseases. The studies were a significant setback for the optimistic view that semaglutide and other GLP-1 drugs could help prevent a number of brain diseases.
Highly Anticipated Alzheimer’s Trials Yield Disappointing Results for GLP-1 DrugHighly Anticipated Alzheimer’s Trials Yield Disappointing Results for GLP-1 Drug
(MedPage Today) — The oral GLP-1 receptor agonist semaglutide (Rybelsus) did not slow Alzheimer’s disease progression in the highly awaited EVOKE phase III trials, Novo Nordisk announced Monday. The company shared topline results from the 2-year… (MedPage Today) — The oral GLP-1 receptor agonist semaglutide (Rybelsus) did not slow Alzheimer’s disease progression in the Read More
Synthetic stress hormone dexamethasone could reduce certain breast cancer metastasesSynthetic stress hormone dexamethasone could reduce certain breast cancer metastases
The drug dexamethasone supplements cancer treatments to alleviate side effects of chemotherapy such as nausea or inflammation. Researchers at the University of Basel, Switzerland, have now discovered that it also fights metastases in certain types of breast cancer.
Patients who discontinue GLP-1s found to have more weight gain, complications during pregnancyPatients who discontinue GLP-1s found to have more weight gain, complications during pregnancy
In a study led by researchers at Mass General Brigham, pregnant individuals who stopped taking popular weight loss GLP-1 medications before or early in their pregnancy tended to gain more weight and have higher risks of diabetes and hypertensive disorders during pregnancy, and experienced preterm delivery more so than people who had never taken GLP-1 Read More
Key immune differences in triple-negative breast cancer uncoveredKey immune differences in triple-negative breast cancer uncovered
Researchers at the LSU LCMC Health Cancer Center have published findings in npj Breast Cancer that shed new light on triple-negative breast cancer (TNBC), one of the most aggressive forms of breast cancer.
New Moms’ GLP-1 Prescriptions Jumped After Wegovy ApprovalNew Moms’ GLP-1 Prescriptions Jumped After Wegovy Approval
(MedPage Today) — Prescriptions for GLP-1 receptor agonists increased among postpartum women once semaglutide (Ozempic, Wegovy) was approved for weight loss, a Danish epidemiological study found. In the first quarter of 2018, there were less… (MedPage Today) — Prescriptions for GLP-1 receptor agonists increased among postpartum women once semaglutide (Ozempic, Wegovy) was approved for Read More
Stopping GLP-1s for Pregnancy Linked to Weight Gain, ComplicationsStopping GLP-1s for Pregnancy Linked to Weight Gain, Complications
(MedPage Today) — The recommended discontinuation of GLP-1 receptor agonists during pregnancy was associated with more gestational weight gain and higher risks of pregnancy complications, according to an analysis of health records that primarily… (MedPage Today) — The recommended discontinuation of GLP-1 receptor agonists during pregnancy was associated with more gestational weight gain and Read More
How to Make Treatment Decisions in Breast Cancer Without Genomic AssaysHow to Make Treatment Decisions in Breast Cancer Without Genomic Assays
(MedPage Today) — In resource-limited settings, genomic assays for hormone receptor-positive, HER2-negative breast cancer aren’t always accessible. Yet treatment decisions still need to be made — often quickly and with limited information…
People who stop using Mounjaro tend to regain weight and lose other health benefits, says studyPeople who stop using Mounjaro tend to regain weight and lose other health benefits, says study
Improvements such as reduced ‘bad’ cholesterol and lower blood pressure go into reverse upon stopping weight-loss jabs People who stop using the weight-loss jab Mounjaro not only tend to regain weight, but experience a reversal in other health improvements too, research suggests. Mounjaro, which contains the active ingredient tirzepatide, has become a popular medication for Read More